SG11202101913PA - INHIBITING aV ß6 INTEGRIN - Google Patents

INHIBITING aV ß6 INTEGRIN

Info

Publication number
SG11202101913PA
SG11202101913PA SG11202101913PA SG11202101913PA SG11202101913PA SG 11202101913P A SG11202101913P A SG 11202101913PA SG 11202101913P A SG11202101913P A SG 11202101913PA SG 11202101913P A SG11202101913P A SG 11202101913PA SG 11202101913P A SG11202101913P A SG 11202101913PA
Authority
SG
Singapore
Prior art keywords
integrin
inhibiting
Prior art date
Application number
SG11202101913PA
Other languages
English (en)
Inventor
Bryce Harrison
James Dowling
Aleksey Gerasyuto
Matthew Bursavich
Dawn Troast
Blaise Lippa
Bruce Rogers
Kristopher Hahn
Cheng Zhong
Qi Qiao
fu-yang Lin
Brian Sosa
Andrea Bortolato
Mats Svensson
Eugene Hickey
Kyle Konze
Tyler Day
Byungchan Kim
Original Assignee
Morphic Therapeutic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphic Therapeutic Inc filed Critical Morphic Therapeutic Inc
Publication of SG11202101913PA publication Critical patent/SG11202101913PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SG11202101913PA 2018-08-29 2019-08-29 INHIBITING aV ß6 INTEGRIN SG11202101913PA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862724423P 2018-08-29 2018-08-29
US201962859457P 2019-06-10 2019-06-10
PCT/US2019/048782 WO2020047239A1 (fr) 2018-08-29 2019-08-29 INHIBITION DE L'INTÉGRINE ανβ6

Publications (1)

Publication Number Publication Date
SG11202101913PA true SG11202101913PA (en) 2021-03-30

Family

ID=67809398

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202101913PA SG11202101913PA (en) 2018-08-29 2019-08-29 INHIBITING aV ß6 INTEGRIN

Country Status (22)

Country Link
US (4) US20200071322A1 (fr)
EP (2) EP3617206A1 (fr)
JP (1) JP7540998B2 (fr)
KR (1) KR20210065935A (fr)
CN (1) CN112805001B (fr)
AU (1) AU2019327475A1 (fr)
BR (1) BR112021003859A2 (fr)
CA (1) CA3109534A1 (fr)
CL (1) CL2021000484A1 (fr)
CO (1) CO2021002706A2 (fr)
CR (1) CR20210109A (fr)
DO (1) DOP2021000035A (fr)
EC (1) ECSP21013620A (fr)
IL (1) IL280782A (fr)
MA (1) MA51066A (fr)
MX (1) MX2021002181A (fr)
PE (1) PE20211640A1 (fr)
PH (1) PH12021550404A1 (fr)
SG (1) SG11202101913PA (fr)
TW (1) TW202035400A (fr)
UY (1) UY38353A (fr)
WO (1) WO2020047239A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018049068A1 (fr) 2016-09-07 2018-03-15 Pliant Therapeutics, Inc. Composés d'acides aminés n-acyle et méthodes d'utilisation
CA3054792A1 (fr) 2017-02-28 2018-09-07 Morphic Therapeutic, Inc. Inhibiteurs de l'integrine .alpha.v.beta.6
MA47697A (fr) 2017-02-28 2020-01-08 Morphic Therapeutic Inc Inhibiteurs de l'(alpha-v)(bêta-6) intégrine
EP4328230A3 (fr) 2018-03-07 2024-04-24 Pliant Therapeutics, Inc. Composés d'acides aminés et procédés d'utilisation
TWI841573B (zh) 2018-06-27 2024-05-11 美商普萊恩醫療公司 具有未分支連接子之胺基酸化合物及使用方法
JP7540998B2 (ja) 2018-08-29 2024-08-27 モーフィック セラピューティック，インコーポレイテッド αｖβ６インテグリンの阻害
TW202028179A (zh) 2018-10-08 2020-08-01 美商普萊恩醫療公司 胺基酸化合物及使用方法
US11179383B2 (en) 2018-10-30 2021-11-23 Gilead Sciences, Inc. Compounds for inhibition of α4β7 integrin
EP3873897B1 (fr) 2018-10-30 2024-08-14 Gilead Sciences, Inc. Dérivés de n-benzoyl-phénylalanine en tant qu'inhibiteurs d'integrin alpha4béta7 pour le traitement de maladies inflammatoires
EP3873900A1 (fr) 2018-10-30 2021-09-08 Gilead Sciences, Inc. Dérivés d'imidazopyridine utilisés en tant qu'inhibiteurs de l'intégrine alpha4bêta7
WO2020092375A1 (fr) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Dérivés de quinoléine utilisés en tant qu'inhibiteurs de l'intégrine alpha4bêta7
CN114222730B (zh) 2019-08-14 2024-09-10 吉利德科学公司 用于抑制α4β7整合素的化合物
JP2023541427A (ja) * 2020-09-11 2023-10-02 アローヘッド ファーマシューティカルズ インコーポレイテッド 骨格筋送達プラットフォーム及び使用方法
CN116710169A (zh) 2020-11-19 2023-09-05 普利安特治疗公司 整合素抑制剂及其用途
WO2024173570A1 (fr) * 2023-02-14 2024-08-22 Morphic Therapeutic, Inc. INHIBITION DE L'INTÉGRINE αVβ8
WO2024173572A1 (fr) * 2023-02-14 2024-08-22 Morphic Therapeutic, Inc. INHIBITION DE L'INTÉGRINE α Vβ8

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4134467A1 (de) 1991-10-18 1993-04-22 Thomae Gmbh Dr K Heterobiarylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
TW221996B (fr) 1991-11-14 1994-04-01 Glaxo Group Ltd
EP0623120A1 (fr) 1992-01-21 1994-11-09 Glaxo Group Limited Derives d'acide piperidineacetique servant d'inhibiteurs de l'agregation plaquettaire sanguine dependante du fibrinogene
ES2134870T3 (es) 1993-05-01 1999-10-16 Merck Patent Gmbh Antagonistas del receptor de adhesion.
US6069143A (en) 1994-12-20 2000-05-30 Smithkline Beecham Corporation Fibrinogen receptor antagonists
TR199801255T2 (xx) 1995-12-29 1998-10-21 Smithkline Beecham Corporation Vitronektin resept�r antagonistleri.
US20010034445A1 (en) 1995-12-29 2001-10-25 Smithkline Beecham Corporation Vitronectin receptor antagonists
CN1209063A (zh) 1995-12-29 1999-02-24 史密丝克莱恩比彻姆公司 玻连蛋白受体拮抗剂
CA2242877A1 (fr) 1996-01-16 1997-07-24 Merck & Co., Inc. Antagonistes du recepteur integrine
ATE212990T1 (de) 1996-03-20 2002-02-15 Hoechst Ag Inhibitoren der knochenresorption und vitronectinrezeptor-antagonisten
UA49006C2 (uk) 1996-03-29 2002-09-16 Файзер Інк. Похідні 6-фенілпіридил-2-аміну, фармацевтична композиція, спосіб інгібування синтази оксиду нітрогену у ссавців та спосіб лікування
WO1998008840A1 (fr) 1996-08-29 1998-03-05 Merck & Co., Inc. Antagonistes de l'integrine
US5952341A (en) 1996-10-30 1999-09-14 Merck & Co., Inc. Integrin antagonists
JP2001503060A (ja) 1996-10-30 2001-03-06 メルク エンド カンパニー インコーポレーテッド インテグリン拮抗薬
AU724216B2 (en) 1997-04-07 2000-09-14 Merck & Co., Inc. A method of treating cancer
AU7105498A (en) 1997-04-14 1998-11-11 Merck & Co., Inc. Combination therapy for the prevention and treatment of osteoporosis
WO1999026945A1 (fr) 1997-11-26 1999-06-03 Du Pont Pharmaceuticals Company 1,3,4-THIADIAZOLES ET 1,3,4-OXADIAZOLES UTILISES COMME ANTAGONISTES DE αvβ¿3?
US6048861A (en) 1997-12-17 2000-04-11 Merck & Co., Inc. Integrin receptor antagonists
WO1999030713A1 (fr) 1997-12-17 1999-06-24 Merck & Co., Inc. Antagonistes du recepteur de l'integrine
JP2002508323A (ja) 1997-12-17 2002-03-19 メルク エンド カムパニー インコーポレーテッド インテグリン受容体拮抗薬
TR200002557T2 (tr) 1997-12-17 2000-12-21 Merck & Co., Inc. İntegrin reseptörü antagonistleri
US6017926A (en) 1997-12-17 2000-01-25 Merck & Co., Inc. Integrin receptor antagonists
DK1040111T3 (da) 1997-12-17 2005-10-10 Merck & Co Inc Integrinreceptorantagonister
US6329372B1 (en) 1998-01-27 2001-12-11 Celltech Therapeutics Limited Phenylalanine derivatives
WO2000006169A1 (fr) 1998-07-29 2000-02-10 Merck & Co., Inc. Antagonistes des recepteurs de l'integrine
GB9825652D0 (en) 1998-11-23 1999-01-13 Celltech Therapeutics Ltd Chemical compounds
BR9916323A (pt) 1998-12-19 2001-10-30 Merck Patent Gmbh Inibidores da integrina alfavbeta6
CA2358855A1 (fr) 1999-02-03 2000-08-10 Merck & Co., Inc. Derives de la benzazepine utilises comme antagonistes du recepteur alpha-v de l'integrine
US6723711B2 (en) 1999-05-07 2004-04-20 Texas Biotechnology Corporation Propanoic acid derivatives that inhibit the binding of integrins to their receptors
US6518283B1 (en) 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
PT1187592E (pt) 1999-06-02 2007-10-19 Merck & Co Inc Antagonistas dos receptores de integrina alfa v
JP2003502373A (ja) 1999-06-23 2003-01-21 メルク エンド カムパニー インコーポレーテッド インテグリン受容体アンタゴニスト
DE19933173A1 (de) 1999-07-15 2001-01-18 Merck Patent Gmbh Cyclische Peptidderivate als Inhibitoren des Integrins alpha¶v¶beta¶6¶
US6514964B1 (en) 1999-09-27 2003-02-04 Amgen Inc. Fused cycloheptane and fused azacycloheptane compounds and their methods of use
GB9929988D0 (en) 1999-12-17 2000-02-09 Celltech Therapeutics Ltd Chemical compounds
WO2001053297A1 (fr) 2000-01-20 2001-07-26 Merck & Co., Inc. Antagonistes du recepteur de l'integrine alpha v
AU780988B2 (en) 2000-01-24 2005-04-28 Merck & Co., Inc. Alpha V integrin receptor antagonists
US7119098B2 (en) 2000-06-15 2006-10-10 Pharmacia Corporation Heteroarylakanoic acids as intergrin receptor antagonists
DE10041423A1 (de) 2000-08-23 2002-03-07 Merck Patent Gmbh Biphenylderivate
US20040254211A1 (en) 2000-09-14 2004-12-16 Arison Byron H Alpha v integrin receptor antagonists
AU2001290772A1 (en) 2000-09-14 2002-03-26 Merck And Co., Inc. Alpha v integrin receptor antagonists
AU2001295038A1 (en) 2000-09-18 2002-03-26 Merck & Co., Inc. Treatment of inflammation with a combination of a cyclooxygenase-2 inhibitor and an integrin alpha-V antagonist
EP1425010B8 (fr) 2001-01-29 2012-03-28 Janssen Pharmaceuticals, Inc. Indoles substitues et utilisation de ceux-ci comme antagonistes d'integrine
DE10112771A1 (de) 2001-03-16 2002-09-26 Merck Patent Gmbh Inhibitoren des Integrins alpha¶v¶beta¶6¶
JP2004528373A (ja) 2001-05-03 2004-09-16 メルク　エンド　カムパニー　インコーポレーテッド ベンズアゼピノンαＶインテグリン受容体拮抗物質
US20040043988A1 (en) 2001-06-15 2004-03-04 Khanna Ish Kurmar Cycloalkyl alkanoic acids as intergrin receptor antagonists
DE10204789A1 (de) 2002-02-06 2003-08-14 Merck Patent Gmbh Inhibitoren des Integrins alpha¶v¶beta6
DK1539739T3 (da) 2002-08-16 2011-03-07 Janssen Pharmaceutica Nv Piperidinylforbindelser, der selektivt binder integriner
FI20041129A0 (fi) 2004-08-30 2004-08-30 Ctt Cancer Targeting Tech Oy Tioksotiatsolidinoniyhdisteitä lääkkeinä käytettäviksi
AR059224A1 (es) 2006-01-31 2008-03-19 Jerini Ag Compuestos para la inhibicion de integrinas y uso de estas
JP2009539815A (ja) 2006-06-09 2009-11-19 アストラゼネカ アクチボラグ 固形腫瘍の治療用のａ５ｂ１アンタゴニストとしてのＮ−（ベンゾイル）−Ｏ−［２−（ピリジン−２−イルアミノ）エチル］−Ｌ−チロシン誘導体と関連化合物
CN101784516B (zh) 2007-06-13 2014-07-02 百时美施贵宝公司 作为凝血因子抑制剂的二肽类似物
ES2428896T3 (es) 2007-11-16 2013-11-12 Ube Industries, Ltd. Compuesto de benzacepinona
US20120289481A1 (en) 2011-05-13 2012-11-15 O'neil Jennifer Compositions and methods for treating cancer
KR20150038185A (ko) 2012-07-18 2015-04-08 세인트 루이스 유니버시티 인테그린 길항제로서의 베타 아미노산 유도체
US8716226B2 (en) 2012-07-18 2014-05-06 Saint Louis University 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists
EP2784511A1 (fr) 2013-03-27 2014-10-01 Universität Zürich Intégrine alpha-v-beta6 pour le diagnostic/pronostic du carcinome colorectal
GB201305668D0 (en) 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
WO2015103643A2 (fr) 2014-01-06 2015-07-09 The General Hospital Corporation Antagonistes de l'intégrine
MA39823A (fr) 2014-04-03 2018-01-09 Janssen Pharmaceutica Nv Dérivés de pyridine macrocyclique
WO2015179823A2 (fr) 2014-05-23 2015-11-26 The California Institute For Biomedical Research Inhibiteurs d'alpha (v) bêta 6, localisés dans les poumons
WO2016022851A1 (fr) 2014-08-06 2016-02-11 Children's Medical Center Corporation Polypeptides d'intégrine modifiés, dimères de polypeptides d'intégrine modifiés, et leurs utilisations
GB201417018D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417002D0 (en) * 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201417011D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417094D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
CN114805342A (zh) 2015-02-19 2022-07-29 赛弗卢尔生命科学公司 氟化四氢萘啶基壬酸衍生物及其用途
ES2877707T3 (es) 2015-03-25 2021-11-17 Fujifilm Corp Método para producir un nuevo compuesto que contiene nitrógeno o una sal del mismo, y producto intermedio de producción del mismo
EP3288555A1 (fr) 2015-04-30 2018-03-07 SciFluor Life Sciences, Inc. Dérivés de l'acide propionique tétrahydronaphthyridinyle et leurs utilisations
BR112018012981A2 (pt) 2015-12-30 2018-12-04 Saint Louis University derivados do ácido meta-azacíclico amino benzoico como antagonistas de pan integrina com melhores propriedades farmacocinéticas
GB201604589D0 (en) 2016-03-18 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical compound
GB201604680D0 (en) * 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
GB201604681D0 (en) * 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
KR20190026001A (ko) 2016-07-05 2019-03-12 더 락커펠러 유니버시티 테트라하이드로나프티리딘펜탄아미드 인테그린 길항물질
WO2018049068A1 (fr) 2016-09-07 2018-03-15 Pliant Therapeutics, Inc. Composés d'acides aminés n-acyle et méthodes d'utilisation
PL3535397T3 (pl) 2016-11-01 2022-03-07 Arrowhead Pharmaceuticals, Inc. Ligandy integryny alfa-v beta-6 i ich zastosowania
WO2018085578A1 (fr) 2016-11-02 2018-05-11 Saint Louis University Inhibiteurs de l'intégrine en combinaison avec un agent qui interagit avec un récepteur de chimiokine
WO2018085552A1 (fr) 2016-11-02 2018-05-11 Saint Louis University Antagonistes de l'intégrine
MX2019005306A (es) 2016-11-08 2019-08-12 Squibb Bristol Myers Co Compuestos mono y espirociclicos que continen ciclobutano y azetidina como inhibidores de la integrina alfa v.
CA3042714A1 (fr) 2016-11-08 2018-05-17 Bristol-Myers Squibb Company Derives d'indazole en tant qu'antagonistes de l'integrine av
ES2898835T3 (es) 2016-11-08 2022-03-09 Bristol Myers Squibb Co Azol amidas y aminas como inhibidores de la integrina alfav
CN110167935B (zh) 2016-11-08 2022-05-27 百时美施贵宝公司 作为αV整合素抑制剂的3-经取代的丙酸
PL3538528T3 (pl) 2016-11-08 2021-05-31 Bristol-Myers Squibb Company Amidy pirolu jako inhibitory integryny alfa v
EP3558303A4 (fr) 2016-12-23 2020-07-29 Pliant Therapeutics, Inc. Composés acides aminés et leurs procédés d'utilisation
US11306084B2 (en) 2016-12-29 2022-04-19 Saint Louis University Integrin antagonists
CA3054792A1 (fr) 2017-02-28 2018-09-07 Morphic Therapeutic, Inc. Inhibiteurs de l'integrine .alpha.v.beta.6
MA47697A (fr) * 2017-02-28 2020-01-08 Morphic Therapeutic Inc Inhibiteurs de l'(alpha-v)(bêta-6) intégrine
EP4328230A3 (fr) 2018-03-07 2024-04-24 Pliant Therapeutics, Inc. Composés d'acides aminés et procédés d'utilisation
TWI841573B (zh) 2018-06-27 2024-05-11 美商普萊恩醫療公司 具有未分支連接子之胺基酸化合物及使用方法
US20210284638A1 (en) 2018-07-03 2021-09-16 Saint Louis University ALPHAvBETA1 INTEGRIN ANTAGONISTS
JP7540998B2 (ja) 2018-08-29 2024-08-27 モーフィック セラピューティック，インコーポレイテッド αｖβ６インテグリンの阻害
WO2020047207A1 (fr) 2018-08-29 2020-03-05 Morphic Therapeutics, Inc. Inhibiteurs de l'intégrine (alpha-v)(bêta -6)
EP3843727A4 (fr) 2018-08-29 2022-08-17 Morphic Therapeutic, Inc. Inhibiteurs de l'intégrine (alpha-v)(bêta-6)
EP3844162A4 (fr) 2018-08-29 2022-05-25 Morphic Therapeutic, Inc. INHIBITORS DE L'INTÉGRINE av beta6
TW202028179A (zh) 2018-10-08 2020-08-01 美商普萊恩醫療公司 胺基酸化合物及使用方法
WO2020210404A1 (fr) 2019-04-08 2020-10-15 Pliant Therapeutics, Inc. Formes posologiques et schémas de traitement pour des composés d'acides aminés

Also Published As

Publication number Publication date
WO2020047239A1 (fr) 2020-03-05
CL2021000484A1 (es) 2021-09-03
US20200385384A1 (en) 2020-12-10
US11739087B2 (en) 2023-08-29
US11021480B2 (en) 2021-06-01
MA51066A (fr) 2020-10-14
US20220073511A1 (en) 2022-03-10
TW202035400A (zh) 2020-10-01
JP7540998B2 (ja) 2024-08-27
EP4086254A1 (fr) 2022-11-09
CR20210109A (es) 2021-06-24
EP3617206A1 (fr) 2020-03-04
US20200071322A1 (en) 2020-03-05
UY38353A (es) 2020-03-31
AU2019327475A1 (en) 2021-03-11
JP2021535141A (ja) 2021-12-16
CO2021002706A2 (es) 2021-05-20
IL280782A (en) 2021-04-29
PE20211640A1 (es) 2021-08-24
BR112021003859A2 (pt) 2021-05-18
DOP2021000035A (es) 2021-06-30
PH12021550404A1 (en) 2021-10-04
CN112805001B (zh) 2024-07-23
CA3109534A1 (fr) 2020-03-05
ECSP21013620A (es) 2021-05-31
MX2021002181A (es) 2021-07-15
US20200354359A1 (en) 2020-11-12
CN112805001A (zh) 2021-05-14
KR20210065935A (ko) 2021-06-04

Similar Documents

Publication Publication Date Title
SG11202101913PA (en) INHIBITING aV ß6 INTEGRIN
GB201806688D0 (en) No details
GB201803663D0 (en) No details
GB201801258D0 (en) No details
GB201813366D0 (en) No details
GB201812685D0 (en) No details
GB202000441D0 (en) No details
GB201721011D0 (en) No details
GB201813269D0 (en) No details
GB201722295D0 (en) m
GB201801628D0 (en) No details
SG11202001400YA (en) Closure
GB201807647D0 (en) No details
GB201718299D0 (en) Stents
GB201714354D0 (en) Siam
GB201918681D0 (en) No details
ZAA201800662S (en) Tab
GB201917069D0 (en) No details
GB201717719D0 (en) No details
GB201802344D0 (en) No details
GB201801239D0 (en) No details
GB201811353D0 (en) No details
GB201720890D0 (en) No details
GB201900248D0 (en) No details
GB201709043D0 (en) No details